{"id":62994,"date":"2026-04-13T19:40:41","date_gmt":"2026-04-13T11:40:41","guid":{"rendered":"https:\/\/flcube.com\/?p=62994"},"modified":"2026-04-13T19:40:42","modified_gmt":"2026-04-13T11:40:42","slug":"merck-kgaa-closes-acquisition-of-jsr-life-sciences-chromatography-business-bolstering-antibody-purification-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62994","title":{"rendered":"Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio"},"content":{"rendered":"\n

Merck KGaA<\/strong> (ETR: MRK<\/a>) has officially closed its acquisition of the chromatography business from JSR Life Sciences<\/strong>, a strategic move to significantly enhance its downstream processing capabilities for biopharmaceutical manufacturing. The deal integrates JSR\u2019s flagship Amsphere Protein A resins<\/strong> and advanced chromatography technologies into Merck\u2019s Process Solutions<\/strong> portfolio, strengthening its position as a leading provider of end-to-end solutions for monoclonal antibody (mAb) production.<\/p>\n\n\n\n

Transaction & Integration Details<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Acquirer<\/strong><\/td>Merck KGaA (ETR: MRK)<\/td><\/tr>
Acquired Business<\/strong><\/td>Chromatography business of JSR Life Sciences<\/td><\/tr>
Key Assets Acquired<\/strong><\/td>Amsphere Protein A resins, advanced Protein A chromatography tech<\/td><\/tr>
Primary Application<\/strong><\/td>Efficient, scalable purification of monoclonal antibodies (mAbs)<\/td><\/tr>
New Team Integration<\/strong><\/td>>50 employees based in Belgium<\/td><\/tr>
Portfolio Integration<\/strong><\/td>Merck\u2019s Process Solutions (Biopharma)<\/td><\/tr>
Customer Impact<\/strong><\/td>Enhanced support from process development to commercial scale<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale<\/h2>\n\n\n\n